RARA Antibody
- Known as:
- RARA Antibody
- Catalog number:
- abx000697
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- RARA Antibody
Related genes to: RARA Antibody
- Gene:
- RARA NIH gene
- Name:
- retinoic acid receptor alpha
- Previous symbol:
- -
- Synonyms:
- RAR, NR1B1
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-09
- Date modifiied:
- 2019-04-23
Related products to: RARA Antibody
Related articles to: RARA Antibody
- Successful implantation requires precise coordination of uterine epithelial receptivity, stromal decidualization, and immune homeostasis during a narrow peri-implantation window. Although retinoic acid (RA) signaling has been implicated in female reproduction, the endogenous and isoform-specific roles of retinoic acid receptors (RARs) remain poorly defined. Here, we combined isoform-specific genetic mouse models, transcriptomic profiling, and functional studies in mouse and human stromal cells to determine how RAR signaling regulates early pregnancy. We found that RARG is the dominant RAR isoform required for female fertility in mice, as its deletion severely impaired implantation, whereas combined loss of all RAR isoforms caused complete reproductive failure. RAR deficiency disrupted multiple sequential reproductive processes, including sperm transport and fertilization, suppression of uterine estrogen receptor activity, acquisition of stromal decidualization competence, and maintenance of uterine immune homeostasis. Transcriptomic analyses identified conserved epithelial and mesenchymal programs altered across independent RAR-deficient mouse models and revealed significant overlap with endometrial gene signatures from women with recurrent implantation failure. In human endometrial stromal cells, suppression of the RARA isoform consistently disrupted decidualization across three independent primary cell lines and an immortalized cell model. Together, these findings identify RAR signaling as a critical regulator of early pregnancy and reveal conserved, isoform-specific functions required for early pregnancy. - Source: PubMed
Publication date: 2026/09/10
Yin YanSo Emily YWolf ElianaRobles Pinos VivianHaller MeadeShang RenjieHewitt Sylvia CTak AlexBany Brent MChen David YShen MengchengDeMayo Francesco JMa Liang - Essential oils (EOs) are unique materials with healing powers that have been extensively reported. Yet their full antimicrobial potential is still underexplored due to their complex molecular properties, high viscosity, and low solubility, which limit their wide pharmaceutical application. In this study, we report the formulation of water-soluble nanoemulsions (NEs) of three EOs, namely, Artemisia vulgaris, Rhododendron anthopogon, and Eremophila mitchellii. The prepared NEs had an average particle diameter between 190 and 230 nm and remained physically stable at 4°C for up to 6 months. Most importantly, the fabricated NEs enhanced the antibacterial activity of the EOs against a multidrug-resistant Staphylococcus aureus clinical isolate by eightfold, with the EO having a median minimum inhibitory concentration (MIC) of 64 mg/mL, whilst the NEs had a median value of 8 mg/mL. Moreover, the NEs reduced the biofilm viability by up to > 6 log compared with the control groups. Among the tested EOs, E. mitchelli showed the strongest antibacterial activity, with MIC values of 16 and < 0.125 mg/mL for the EO and NE, respectively. In addition, E. mitchellii NE nearly eradicated S. aureus biofilms at 10 mg/mL across all strains. Safety studies against human foreskin fibroblasts indicated a harmless effect of the excipients used in the fabrication process, where the viability of cells exposed to the NEs of E. mitchellii and A. vulgaris was > 70% and 90%, respectively. These findings highlight the successful fabrication of EO-based NEs with potent antibacterial activity against multidrug-resistant S. aureus clinical isolates in vitro. - Source: PubMed
Karki SumeenaRamezanpour MahnazCooksley Clare MBarry EmmaPrestidge Clive ANepal RoshanFeizi SholehCorrell DianneWormald Peter-JohnVreugde SarahAwad Muhammed - Acute promyelocytic leukemia (APL) is a hematological emergency requiring prompt diagnosis and initiation of all-trans retinoic acid (ATRA) therapy to prevent life-threatening hemorrhage. While diagnosis is traditionally confirmed by identifying the t(15;17)(q24;q21) translocation or PML::RARα fusion, practical challenges-especially in resource-limited settings-necessitate an integrated, multimodal diagnostic approach. A retrospective analysis was conducted on seven APL cases diagnosed between 2022 and 2024. Diagnostic evaluation incorporated complete blood counts (CBC), peripheral smear and bone marrow morphology (MGG staining), cytochemistry (MPO, PAS), immunophenotyping by flow-cytometry, and molecular/cytogenetic confirmation via karyotyping, FISH, and RT-PCR. Cases were analyzed for morphological variants, test accessibility, and diagnostic concordance across modalities. The median patient age was 29 years (range: 13-70); 4 males and 3 females. Morphology revealed hypergranular (5/7) and hypogranular (2/7) variants. CBC scatterplots and strong MPO positivity supported initial diagnostic suspicion. Flow-cytometry typically showed a CD34-/HLA-DR - profile, with one atypical CD34+/HLA-DR + case. PML::RARα fusion was confirmed in 4/5 cases by FISH and in one FISH-negative case by RT-PCR (bcr3 variant). Karyotyping revealed t(15;17) in 4/4 cases, with additional trisomy 8 in two. Each modality contributed uniquely, with final diagnoses supported by at least two complementary methods in 6/7 cases. Morphological and scatterplot patterns are suggestive but may be ambiguous in hypogranular APL. Cytochemistry, flow-cytometry, and rapid molecular diagnostics (FISH, RT-PCR) are critical for timely confirmation. An integrated, stepwise diagnostic algorithm enhances accuracy and feasibility, especially in constrained settings, as demonstrated by our case series. - Source: PubMed
Publication date: 2025/12/11
Kulkarni JayashreeJ GayathriKumari PrasannaKorlimarla Aruna - Acute promyelocytic leukemia (APL) is defined by the PML-RARα fusion gene, which serves as a key biomarker for pathogenesis, diagnosis, and measurable residual disease (MRD) monitoring. The incorporation of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has markedly transformed treatment outcomes. However, treatment-related toxicities frequently lead to treatment interruptions that may lead to persistent MRD post-induction therapy. This study investigates whether variations in doses are associated with persistent MRD. Additionally, statistical modelling is utilized to find the ideal dose and duration of ATRA for induction, to balance drug toxicity and response. - Source: PubMed
Publication date: 2025/11/26
Gupta PrakharGhosh ShouriyoRoy SabyasachiDas PoonamPoddar DibakarChattopadhyay DebranjaniKumar JeevanNag ArijitGhara NiharenduNair ReenaRath AsishVinarkar SushantParihar MayurMishra Deepak Kumar - Acute promyelocytic leukemia (APL) is defined by its genetics, yet interphase fluorescence hybridization (FISH) for the PML::RARA fusion, the chromosomal complement seen on a metaphase spread, and the marrow's cellular composition on a Wright-Giemsa smear are read as separate, unconnected examinations. We did not identify a published model trained on two or more of these image types in the same patients with APL. - Source: PubMed
Publication date: 2026/08/24
Gao MinjieOuyang GuifangLiu YangguangChen Shikun